Nov 2026· Digestive and Liver Disease· 0 citations· 22 references
Medicine
TL;DR
NICT was associated with improved survival compared with either NCT or CCRT, and these findings are hypothesis-generating and require prospective validation.
Abstract
Purpose
To compare the efficacy between neoadjuvant immunochemotherapy (NICT), neoadjuvant chemotherapy (NCT), and concurrent chemoradiotherapy (CCRT) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Materials And Methods
We retrospectively analyzed patients with stage II-IVA disease treated between January 2013 and May 2024. Patients were categorized into the CCRT, NCT, and NICT groups. Survival outcomes were compared using Kaplan-Meier analysis and Cox proportional hazards models.
Results
A total of 347 patients were included: 214 (61.7%) in the CCRT group, 42 (12.1%) in the NCT group, and 91 (26.2%) in the NICT group. Compared with CCRT, NICT was associated with improved disease-free survival (HR = 0.57, 95% CI: 0.41-0.80, P = 0.001) and overall survival (HR = 0.48, 95% CI: 0.32-0.72, P < 0.001). Compared with NCT, NICT was associated with improved disease-free survival (HR = 0.51, 95% CI: 0.32-0.79, P = 0.003) and overall survival (HR = 0.40, 95% CI: 0.24-0.65, P < 0.001). The survival benefit associated with NICT was observed in patients who received >3 cycles (HR = 0.31, 95% CI: 0.15-0.63, P = 0.001).
Conclusion
NICT was associated with improved survival compared with either NCT or CCRT. These findings are hypothesis-generating and require prospective validation.
BACKGROUND
Neoadjuvant chemoradiotherapy (NCRT) is the standard regimen for locally advanced esophageal squamous cell carcinoma (ESCC), while neoadjuvant immunochemotherapy (NICT) has emerged as a promising alternative. Achieving pathological complete response (pCR) after neoadjuvant therapy is associated with favorabl...
Pin-Hao Fang, Xin Xiao, Cheng-Yi Mao et al.· Journal of Thoracic and Card...· 0 citations
Introduction This study consecutively enrolled patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC) treated at Fujian Medical University Union Hospital and Gaozhou People's Hospital between January 1, 2,019, and January 1, 2022. Methods All patients received neoadjuvant therapy followed b...
Hai Zhang, Yun Liang, Chao-Lin Li et al.· Frontiers in Medicine· 0 citations
Although PORT did not significantly improve survival in the overall cSCLN+ population, a trend toward improved OS was observed in the cSCLN+pSCLN+ subgroup, suggesting PORT may be considered as a potential strategy to improve survival outcomes.
Yi-Meng Yu, Lin Lin, Ya Zeng et al.· Annals of Surgical Oncology· 0 citations
The optimal treatment strategy for elderly patients (aged ≥65 years) with operable locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. This study aimed to compare the survival outcomes of upfront surgery (US), neoadjuvant chemoimmunotherapy (nCIT), and neoadjuvant chemoradiotherapy (nC...
Z. Hou, Yi-Xiang Zhu, M. Lan et al.· Frontiers in Immunology· 0 citations